Skip to main content
Stonvex
Loading…
Home
Markets
Screener
Portfolio
Community
Stonvex publishes market data and research only.
Not investment advice. Not a registered investment advisor.
Read disclaimer
.
Stonvex
Search...
Cmd K
Search...
Cmd K
← Back to rankings
NGEN
Live
Save
Overview
Financials
Filings
Earnings Calls
Short Interest
Ownership
Ratings
Peers
News
Log in
Get Started
Loading latest news…
52w low +6.6%
NGEN
NervGen Pharma Corp. Common stock
☁️ News word cloud
Top words across the last 50 articles for this ticker.
spinal
cord
injury
therapies
market
treatment
rogers
emerging
critical
growth
rgma
inhibitor
nervgen
pharma
adam
chief
executive
officer
execution
appointment
StonvexStonvexStonvexStonvex